France has canceled a pre-order for 50,000 doses of Merck & Co's molnupiravir to treat COVID-19. The French Ministry of Health attributed its decision to evidence that the drug reduces the risk of hospitalization or death by only 30%. Instead of molnupiravir, France ordered Pfizer's rachlorovid, which demonstrated a 90% reduction in that risk.